Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CES2 | O00748 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | AADAC | P22760 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flutamide SCHEMBL1461845 | 1.00 | AR (1.00) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL3934 | 1.00 | AR (1.00) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL28162762 | 0.99 | AR (0.97) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL21753660 | 0.99 | AR (0.97) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL679388 | 0.96 | AR (0.93) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL7104567 | 0.95 | AR (0.90) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL1028216 | 0.93 | AR (0.86) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL11512367 | 0.91 | AR (0.83) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL19117466 | 0.90 | AR (0.81) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL11512254 | 0.90 | AR (0.81) | ARCYP3A4CES2ABCB11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4467200-B1 | EZH2 INHIBITION THERAPIES FOR THE TREATMENT OF ANDROGEN RECEPTOR MUTATED PROSTATE CANCERS | CONSTELLATION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4525938-B1 | RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | BAYER AG (DE) | 2026-03-11 | — | — | EP | claimed |
| EP-3277381-B1 | NITROBENZYL DERIVATIVES OF ANTI-CANCER AGENTS | OBI PHARMA INC (TW) | 2026-01-07 | — | — | EP | claimed |
| EP-4282490-B1 | FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY | ETH ZUERICH (CH) | 2025-11-12 | — | — | EP | claimed |
| EP-3046572-B1 | CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF | BLAZE BIOSCIENCE INC (US) | 2025-07-30 | — | — | EP | claimed |
| EP-3710001-B1 | COMPOUNDS AND METHODS FOR REGULATING, LIMITING, OR INHIBITING AVIL EXPRESSION | UNIV VIRGINIA PATENT FOUNDATION (US) | 2025-06-18 | — | — | EP | claimed |
| EP-3462875-B1 | DEVICE FOR ATTRACTING A RODENT | GRIES GERHARD J (CA) | 2025-05-07 | — | — | EP | claimed |
| EP-3426657-B1 | 2 AMINO N [7 METHOXY 2, 3-DIHYDROIMIDAZO-[1, 2-C]QUINAZOLIN-5-YL]PYRIMIDINE 5 CARBOXAMIDES | Bayer Pharma AG (DE) | 2022-07-13 | — | — | EP | claimed |
| EP-4015643-A1 | METHOD FOR OBTAINING A METABOLIC PRODUCT FROM FUNGAL CELLS | Helmholtz-Zentrum für Umweltforschung GmbH-UFZ (DE) | 2022-06-22 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3288558-B1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma AG (DE) | 2022-05-11 | — | — | EP | claimed |
| EP-3319965-B1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2022-05-04 | — | — | EP | claimed |
| CN-114401633-A | Pest control method, pest control agent composition, and pest control agent set | 日本曹达株式会社 | 2022-04-26 | — | — | CN | claimed |
| EP-3373932-B1 | CRYSTALLINE FORM OF A SUBSTITUTED QUINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3370768-B9 | ANTIBODIES SPECIFICALLY BINDING PD-1 AND THEIR USES | JANSSEN BIOTECH INC (US) | 2022-03-16 | — | — | EP | claimed |
| EP-3712151-B1 | (S)-1'-(8-((2-AMINO-3-CHLOROPYRIDIN-4-YL)THIO)IMIDAZO[1,2-C]PYRIMIDIN-5-YL)-5,7-DIHYDROSPIRO[CYCLOPENTA[B]PYRIDINE-6,4'-PIPERIDINE]-5-AMINE AS SHP2 INHIBITOR FOR THE TREATMENT OF CANCER | ETERN BIOPHARMA SHANGHAI CO LTD (CN) | 2022-03-02 | — | — | EP | claimed |
| EP-3693375-B1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | CALITHERA BIOSCIENCES INC (US) | 2022-02-16 | — | — | EP | claimed |